Cantor projects Aquestive shares could rise over 200% in 2025 with Anaphylm approval. Anaphylm is a portable, easy-to-use sublingual epinephrine for Type 1 allergic reactions. China’s new tariffs just ...

Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was ...

Arcus Biosciences ( ($RCUS) ) just unveiled an update. On October 6, 2025, Arcus Biosciences presented updated data from its ARC-20 Phase 1/1b ...

APG808 resulted in a rapid and durable decrease from baseline in FeNO and pSTAT6 measurements throughout the 12 weeks.

An announcement from HUTCHMED (China) ( ($HK:0013) ) is now available. HUTCHMED announced that it will present new and updated clinical data from ...

As CF treatment duration extends, registry-based analyses will need to track pathogen-specific trends and long-term disease ...

On Tuesday, Amgen Inc. AMGN reported mixed second-quarter results. BMO Capital Markets writes, “A commercially in-line quarter for Amgen underscores the importance of upcoming clinical readouts in ...

New clinical data for zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, demonstrates acceptable safety, tolerability, and encouraging initial antitumor activity in patients with KRAS G12D ...